These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 15183334)

  • 1. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.
    Nassar AE; Kamel AM; Clarimont C
    Drug Discov Today; 2004 Dec; 9(23):1020-8. PubMed ID: 15574318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using in vitro human tissues to predict pharmacokinetic properties.
    Huebert ND; Dasgupta M; Chen Y
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):69-74. PubMed ID: 14982150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico prediction of ADME properties: are we making progress?
    Beresford AP; Segall M; Tarbit MH
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):36-42. PubMed ID: 14982146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The graphical representation of ADME-related molecule properties for medicinal chemists.
    Ritchie TJ; Ertl P; Lewis R
    Drug Discov Today; 2011 Jan; 16(1-2):65-72. PubMed ID: 21074634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting drug-drug interactions in drug discovery: where are we now and where are we going?
    Hutzler M; Messing DM; Wienkers LC
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):51-8. PubMed ID: 15679172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development.
    Ekins S; Williams AJ
    Lab Chip; 2010 Jan; 10(1):13-22. PubMed ID: 20024044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 16. New horizons in drug metabolism, pharmacokinetics and drug discovery.
    Palmer AM
    Drug News Perspect; 2003; 16(1):57-62. PubMed ID: 12682673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput screening for lead optimization: a rational approach.
    Bajpai M; Adkison KK
    Curr Opin Drug Discov Devel; 2000 Jan; 3(1):63-71. PubMed ID: 19649839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of ADME evaluation in translation research of innovative drug].
    Liu Y; Hong L; Yu LS; Jiang HD; Chen JZ; Meng Q; Chen SQ; Zeng S
    Yao Xue Xue Bao; 2011 Jan; 46(1):19-29. PubMed ID: 21465804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitigating permeability-mediated risks in drug discovery.
    Wang J; Skolnik S
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):171-87. PubMed ID: 20064074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.